Can Psychedelics Cure? (NOVA Documentary)

"Can Psychedelics Cure?" is a PBS "NOVA" documentary tracing renewed scientific interest in psychedelic-assisted therapy, following patients treated with psilocybin and MDMA for alcohol use disorder, cancer-related depression, and PTSD. It draws on clinical trial data from NYU, Johns Hopkins, and MAPS, plus brain research and the history of Indigenous peyote use. The film reports encouraging early results while its own scientists caution the evidence base is still developing.

From Counter-Culture to Clinical Trials

LSD was discovered by accident in 1943 when Swiss chemist Albert Hofmann absorbed a small amount while researching an unrelated compound. Research into LSD for alcoholism grew through the 1970s before the CIA's MKUltra program tested it on unwitting subjects, it spread into counter-culture, and the 1970 Controlled Substances Act classified psychedelics alongside heroin, while alcohol and tobacco were left out. Decades later, clinicians argue these substances may hold real therapeutic potential. Psychiatrist Rachel Yehuda calls it a puzzle: "How do you shift from these drugs are illegal, these drugs are bad for you, to these drugs are therapeutic, this is the way that you heal from mental illness?" See /medicine/lsd for more.

Psilocybin in Clinical Trials

The film follows Jon Kostas, who struggled with alcohol use disorder from his teens, through an NYU trial led by Stephen Ross and Michael Bogenschutz. Over 12 weeks of therapy including two psilocybin sessions, Kostas describes a symbolic moment, a liquor bottle dissolving into desert sand, that he credits toward a sobriety he says has held since. Across the trial's 93 participants, Ross reports the psilocybin group "had a 50% reduction in drinking compared to just the group that got psychotherapy alone," an effect Bogenschutz calls larger than currently approved medications. Separately, oncologist Manish Agrawal runs a group psilocybin trial for depression connected to cancer; of 30 patients treated, 82% showed more than a 50% reduction in depression symptoms, with improved anxiety and quality of life. See /medicine/psilocybe-cubensis for more.

What Happens in the Brain

Most classic psychedelics, though not MDMA, are described as binding to the serotonin 2A receptor and altering communication between brain regions. Neuroscientist Yasmin Hurd explains chronic alcohol use can shrink nerve connections between regions, leaving the amygdala (the brain's fear and craving center) more reactive as the prefrontal cortex's regulating influence weakens; psychedelics may help regrow these connections. Researcher Matthew Johnson connects this to the default mode network, tied to self-referential thought, which imaging shows quiets under psilocybin as communication elsewhere increases. Fred Barrett's work points to the claustrum, a thin, densely connected tissue layer, as a coordinating hub psychedelics may disrupt, "almost as if the switchboard walks away." See /topics/default-mode-network for more.

Indigenous Roots and the Importance of Setting

The film turns to peyote, a slow-growing cactus used ceremonially by Indigenous peoples in North America. Adrian Primeaux, from a family of "peyote people," calls it "a very intimate medicinal herb" used "to synchronize with the universe." The film covers a land purchase securing peyote access for the Native American Church, and researchers cite this tradition as an influence on the clinical emphasis on setting: the environment, preparation, and intention shaping modern psychedelic therapy. See /articles/set-and-setting-guide for more.

MDMA-Assisted Therapy for PTSD

MAPS, founded by Rick Doblin in 1986, developed MDMA-assisted therapy for PTSD; MDMA is described as raising oxytocin and calming an overactive amygdala, letting the prefrontal cortex regulate fear responses. Marine veteran Scott Ostrom, who developed combat-related PTSD in Fallujah, Iraq, describes confronting a symbolic image of suppressed trauma and reframing a defensive persona he calls "the Bully." The film reports nearly 70% of MAPS phase three participants no longer qualified for a PTSD diagnosis afterward, an effect Doblin says held "regardless of the cause of PTSD." It also follows efforts to extend this therapy to communities of color, including therapist Sara Reed's culturally informed work with Kanu Caplash, who developed PTSD after racist bullying and sexual assault and credits the process with helping him access difficult memories. See /medicine/mdma for more.

Caution Amid the Promise

Its scientists stress limits even as the film reports encouraging results. People with a personal or family history of psychosis, schizophrenia, or bipolar disorder are excluded over a possible, though not yet observed, risk of a psychotic episode. Psychologist Monnica Williams frames psychedelics as powerful medicines, not an escape "into a world with clouds and unicorns," warning that power to heal "could also cause harm." Yehuda closes: "We're not going to have this whole jigsaw puzzle completed for a while... the less we kind of interpret, and the more we just state what our observations are, I think the better off we're going to be." As of the film's reporting, MDMA therapy for PTSD was in final FDA review and psilocybin therapy for depression was in the FDA pipeline, neither yet approved.

Key takeaways

• ●An NYU trial reported psilocybin plus psychotherapy produced a 50% greater reduction in drinking than psychotherapy alone for alcohol use disorder.
• ●Classic psychedelics (not MDMA) bind to the serotonin 2A receptor and quiet the default mode network, a brain system tied to self-referential thought.
• ●Fred Barrett's research points to the claustrum as a possible hub coordinating this shift, though the mechanism remains an active area of study.
• ●In Manish Agrawal's cancer-related depression trial, 82% of 30 patients showed more than a 50% reduction in depression symptoms.
• ●MDMA-assisted therapy through MAPS reportedly helped nearly 70% of phase three PTSD trial participants no longer meet PTSD diagnostic criteria.
• ●The film traces contemporary therapy protocols partly to Indigenous peyote ceremonies, cited as an influence on the clinical emphasis on set and setting.
• ●People with a personal or family history of psychosis are excluded from these trials, and the evidence base is described as still developing.